Literature DB >> 28855217

Decreased severity of Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) in a child with type 1 von Willebrand disease.

Matthew A Geramita1, Johannes Hofer2, James Cooper3, Michael L Moritz3.   

Abstract

Shiga toxin-producing Escherichia coli-associated haemolytic uraemic syndrome (STEC-HUS) is characterised by haemolytic anaemia, thrombocytopenia and acute kidney injury. Von Willebrand Factor (vWF) is an important mediator of normal thrombi formation and indirect evidence suggests that vWF may play an important role in Shiga toxin-induced thrombi formation. Clinical evidence supporting the role of vWF in STEC-HUS is lacking. A 10-year-old girl with type 1 von Willebrand Disease (vWD) had a mild case of STEC-HUS, with nadir haemoglobin 7.3 g/dL and platelet count 105×109 cells/L and peak serum creatinine 0.56 mg/L and lactate dehydrogenase 741 U/L. This is the first report of STEC-HUS in a patient with vWD. We speculate that the quantitative deficiency of vWF associated with type 1 vWD may have attenuated the course of disease by reducing platelet aggregation, complement activation and thrombi formation. This case adds to a growing literature supporting a link between vWF and STEC-HUS. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  acute renal failure; foodborne infections; haematology (incl blood transfusion); infection (gastroenterology)

Mesh:

Year:  2017        PMID: 28855217      PMCID: PMC5589045          DOI: 10.1136/bcr-2017-221043

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice.

Authors:  C V Denis; P André; S Saffaripour; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

2.  Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways.

Authors:  Fang Liu; Jing Huang; J Evan Sadler
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

3.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings.

Authors:  N Banatvala; P M Griffin; K D Greene; T J Barrett; W F Bibb; J H Green; J G Wells
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

4.  Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.

Authors:  Leticia H Nolasco; Nancy A Turner; Aubrey Bernardo; Zhenyin Tao; Thomas G Cleary; Jing-Fei Dong; Joel L Moake
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

5.  Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.

Authors:  Marina Morigi; Miriam Galbusera; Sara Gastoldi; Monica Locatelli; Simona Buelli; Anna Pezzotta; Chiara Pagani; Marina Noris; Marco Gobbi; Matteo Stravalaci; Daniela Rottoli; Francesco Tedesco; Giuseppe Remuzzi; Carlamaria Zoja
Journal:  J Immunol       Date:  2011-06-03       Impact factor: 5.422

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Gastrointestinal manifestations of hemolytic uremic syndrome: recognition of pancreatitis.

Authors:  S Grodinsky; A Telmesani; W L Robson; G Fick; R B Scott
Journal:  J Pediatr Gastroenterol Nutr       Date:  1990-11       Impact factor: 2.839

Review 8.  Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome.

Authors:  H Trachtman; E Christen
Journal:  Curr Opin Pediatr       Date:  1999-04       Impact factor: 2.856

Review 9.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

10.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Authors:  Angela Gerber; Helge Karch; Franz Allerberger; Hege M Verweyen; Lothar B Zimmerhackl
Journal:  J Infect Dis       Date:  2002-08-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.